• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Ypsomed increases auto-injector production in Germany

October 17, 2024 By Sean Whooley

Ypsomed Schwerin auto-injector facility
The Schwerin auto-injector production facility. [Image courtesy of Ypsomed]
Ypsomed announced today that it opened a new production hall at its German site in Schwerin to increase auto-injector production.

The Burgdorf, Switzerland-based company said its expansion enables an increase in production capacity to meet growing global demand. CEO Simon Michel also said the company plans to further expand the plant in the coming years.

Ypsomed invested approximately $25.4 million (22 million CHF) in the new production hall, called Hall D. It extends upon the existing Halls A-C with 30 state-of-the-art plastic injection molding machines and three assembly lines. The company says it can produce an additional 100 million auto-injectors per year in Schwerin.

According to a news release, the company plans to begin construction on “Schwerin II” in January 2025. The first phase expands the production area by 25,000 square meters. It also adds a fully automated high-bay warehouse, an administration building and a central technical building.

Ypsomed’s second construction phase, expected to kick off in 2027 or 2028, adds a further 17,000 square meters. This could increase the company’s production capacity by 400 million to 500 million pens and autoinjectors per year. The company said its investment sum amounts to almost half a billion Swiss francs, or about $578 million.

Initially, the company expects to create 85 new jobs and apprenticeships in Schwerin with the newly opened production hall. It anticipates about 350 new jobs created through the first phase of the Schwerin II project. The new expansions also feature sustainable aspects, such as photovoltaic systems on the roofing and a planned wind turbine. Ypsomed also plans to make Hall D a CO2-neutral building.

“The expansion of our Schwerin site is an important step in our growth strategy, which will enable us to increase our production capacity and expand further in the coming years,” said Michel.

Filed Under: Auto-injectors, Business/Financial News, Drug-Device Combinations, Featured Tagged With: Ypsomed

IN CASE YOU MISSED IT

  • Insulet’s Omnipod Discover data platform begins full US rollout
  • BD’s IV catheters plant in Utah marks 70 years
  • Novo taps Nanexa for long-acting obesity injectables with €1.17B pact
  • Abbott partners with Berry Street to add nutrition coaching to Lingo
  • Dexcom CFO to expand into COO role

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS